MX2019001169A - Formulacion novedosa para administracion por via oral. - Google Patents

Formulacion novedosa para administracion por via oral.

Info

Publication number
MX2019001169A
MX2019001169A MX2019001169A MX2019001169A MX2019001169A MX 2019001169 A MX2019001169 A MX 2019001169A MX 2019001169 A MX2019001169 A MX 2019001169A MX 2019001169 A MX2019001169 A MX 2019001169A MX 2019001169 A MX2019001169 A MX 2019001169A
Authority
MX
Mexico
Prior art keywords
orally administrable
formulation
particles
administrable formulation
pharmaceutical agent
Prior art date
Application number
MX2019001169A
Other languages
English (en)
Inventor
Greenspoon Allen
Original Assignee
Greenspoon Allen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenspoon Allen filed Critical Greenspoon Allen
Publication of MX2019001169A publication Critical patent/MX2019001169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una formulación de goma de mascar administrable por vía oral que comprende una base de goma aceptable farmacéuticamente y partículas de un agente farmacéutico que varían en tamaño de aproximadamente 50 a aproximadamente 2000 µm, en donde la formulación comprende aproximadamente 0.5-30 % en peso de las partículas del agente farmacéutico. Se proporciona, además, una formulación líquida que comprende partículas de un agente farmacéutico.
MX2019001169A 2016-07-28 2017-07-28 Formulacion novedosa para administracion por via oral. MX2019001169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/222,019 US9833408B1 (en) 2016-07-28 2016-07-28 Orally administrable formulation
PCT/CA2017/050904 WO2018018152A1 (en) 2016-07-28 2017-07-28 Novel orally administrable formulation

Publications (1)

Publication Number Publication Date
MX2019001169A true MX2019001169A (es) 2019-08-29

Family

ID=60451833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001169A MX2019001169A (es) 2016-07-28 2017-07-28 Formulacion novedosa para administracion por via oral.

Country Status (13)

Country Link
US (2) US9833408B1 (es)
EP (2) EP4353221A2 (es)
JP (2) JP7050777B2 (es)
AU (2) AU2017301239B2 (es)
BR (2) BR122020007418B1 (es)
CL (1) CL2019000209A1 (es)
CO (1) CO2019001895A2 (es)
CU (1) CU20190005A7 (es)
IL (1) IL264484A (es)
MX (1) MX2019001169A (es)
PE (1) PE20190738A1 (es)
WO (1) WO2018018152A1 (es)
ZA (2) ZA201901116B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11699166B2 (en) 2017-10-09 2023-07-11 American Express Travel Related Services Company, Inc. Multi-merchant loyalty point partnership
US11449887B2 (en) 2017-10-09 2022-09-20 American Express Travel Related Services Company, Inc. Systems and methods for loyalty point distribution
US11397962B2 (en) 2017-10-09 2022-07-26 American Express Travel Related Services Company, Inc. Loyalty point distributions using a decentralized loyalty ID
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US11951086B2 (en) * 2018-04-03 2024-04-09 Pure Green Pharmaceuticals, Inc. Tablet or composition having n-acyl ethanolamine and cannabinoid
EP3549579A1 (en) * 2018-04-03 2019-10-09 Sanofi Winthrop Industrie Oral gum formulation and fabrication process thereof
US11728995B2 (en) 2018-04-09 2023-08-15 American Express Travel Related Services Company, Inc. Reward point transfers using blockchain
US10783545B2 (en) 2018-04-19 2020-09-22 American Express Travel Related Services Company, Inc. Reward point redemption for cryptocurrency
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11013685B2 (en) * 2019-01-25 2021-05-25 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
AU2019424547B2 (en) * 2019-01-25 2023-06-22 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
WO2020151793A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Chewing gum with improved delivery of cannabinoids
CN113365503A (zh) * 2019-01-25 2021-09-07 诺狄更斯公司 具有高强度甜味剂的大麻素口香糖
US11406593B2 (en) 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
US11154496B2 (en) * 2019-01-25 2021-10-26 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
EP3914088A1 (en) * 2019-01-25 2021-12-01 NordicCan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
EP3876743B1 (en) * 2019-01-25 2023-06-07 NordicCan A/S Cannabinoid chewing gum with sugar alcohols
US11191720B2 (en) 2019-01-25 2021-12-07 Nordiccan A/S Chewing gum with improved delivery of cannabinoids
US11471405B2 (en) 2019-03-01 2022-10-18 Nordiccan A/S Tableted chewing gum with enhanced delivery of cannabinoids
US10933017B2 (en) 2019-03-01 2021-03-02 Nordiccan A/S Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US10799450B2 (en) 2019-03-01 2020-10-13 Medcan Pharma A/S Tableted cannabinoid chewing gum with layered structure
US11253473B2 (en) * 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
US11331309B2 (en) 2019-06-05 2022-05-17 Cure Pharmaceutical Holding Corp. Methods and compositions for improving sleep
US20220273558A1 (en) * 2019-08-02 2022-09-01 Advanced Female Technologies Llc Chewing Gum Compositions Containing Cannabinoids
WO2021084543A1 (en) * 2019-10-31 2021-05-06 M. Mustix Ltd Treatment of tooth decay using a chewing gum composition comprising cannabinoids
WO2021116825A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
WO2022072031A1 (en) 2020-10-01 2022-04-07 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing, product, and method of making the same
US11058142B1 (en) 2020-10-01 2021-07-13 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CA3198547A1 (en) * 2020-11-16 2022-05-19 Mark RIDALL Rapidly infusing platform and compositions for therapeutic treatment in humans
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
CA3234805A1 (en) * 2021-10-11 2023-04-20 C. Russell Thomas Biphasic compositions comprising one or both of carbonate and phosphate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816265A (en) * 1986-12-23 1989-03-28 Warner-Lambert Company Sweetener delivery systems containing polyvinyl acetate
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US6132762A (en) * 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
HU228237B1 (en) * 2000-03-09 2013-02-28 Gw Pharma Ltd Pharmaceutical compositions comprising cannabis and a pump spray device for the delivery of the compositions
KR20030059318A (ko) * 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
HU227452B1 (en) * 2001-02-14 2011-06-28 Gw Pharma Ltd Mucoadhesive pharmaceutical formulation
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2659775A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
BRPI0910094B1 (pt) * 2008-03-26 2021-08-10 Stichting Sanammad Composição de goma de mascar, e, blíster
WO2010023689A2 (en) * 2008-08-29 2010-03-04 Sun Pharma Advanced Research Company Limited Microparticles
JP5614571B2 (ja) 2009-12-25 2014-10-29 ダイヤ製薬株式会社 咀嚼用ガム医薬品および咀嚼用ガム医薬品の製造方法
JP2014506894A (ja) 2011-02-28 2014-03-20 テクノロジーズ・クロロス・インク 口腔吸収用の咀嚼可能なビヒクル
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
EP4137142A1 (en) 2013-03-14 2023-02-22 Purple Mundo, Inc. Bioactive concentrates and uses thereof
US20160199299A1 (en) * 2015-01-09 2016-07-14 Mark B. Uren Cannabis Infused Chewing Composition
CN105124747B (zh) 2015-07-21 2018-04-10 中国烟草总公司广东省公司 一种烟草提取物微粒和胶基型口香烟及其制备方法
CA3025559C (en) * 2016-05-27 2023-08-01 Medcan Pharma A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
CA3028160C (en) * 2016-07-28 2021-03-30 Allen Greenspoon Orally administrable formulation

Also Published As

Publication number Publication date
ZA201901116B (en) 2020-10-28
EP3490539A1 (en) 2019-06-05
WO2018018152A1 (en) 2018-02-01
BR112019001572A2 (pt) 2019-05-07
US10456357B2 (en) 2019-10-29
EP3490539A4 (en) 2020-08-12
BR122020007418B1 (pt) 2021-11-03
IL264484A (en) 2019-02-28
CL2019000209A1 (es) 2019-09-27
US20180064645A1 (en) 2018-03-08
AU2017301239B2 (en) 2020-10-08
AU2020257071B2 (en) 2021-03-25
US9833408B1 (en) 2017-12-05
JP2022088537A (ja) 2022-06-14
ZA202001037B (en) 2020-07-29
JP7050777B2 (ja) 2022-04-08
EP3490539B1 (en) 2024-03-13
AU2020257071A1 (en) 2020-11-19
CO2019001895A2 (es) 2019-05-31
JP2019525963A (ja) 2019-09-12
CU20190005A7 (es) 2020-03-04
AU2017301239A1 (en) 2019-03-14
BR112019001572B1 (pt) 2021-11-03
EP4353221A2 (en) 2024-04-17
PE20190738A1 (es) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2019001169A (es) Formulacion novedosa para administracion por via oral.
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2015184127A3 (en) Stable cannabinoid formulations
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
WO2015120110A3 (en) Novel pharmaceutical formulations
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
NZ631100A (en) Soft chewable pharmaceutical products
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EA202090984A1 (ru) Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
PH12020550341A1 (en) Niraparib formulations
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
MY197663A (en) Pharmaceutical formulation
WO2015119924A3 (en) Fixed-dose combinations of antiviral compounds
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2021092242A3 (en) Ror gamma t inhibitors and topical uses thereof
WO2019004984A3 (en) PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof